Por Antitrust Team, em News
CADE closed a sham litigation investigation against Genzyme. The company was accused by EMS and Germed of launching judicial and administrative lawsuits, promoting smear campaign, predatory pricing and product switching to block competitors in the domestic market for sevelamer hydrochloride drugs, which treat high phosphate levels in the blood.
R. Borges Lagoa 1328
São Paulo SP Brasil
04038-904
T 55 11 5086-5000
F 55 11 5086-5555
Av. Paulista 2421
8º andar
São Paulo SP Brasil
01311-300
T 55 11 3291-1000
F 55 11 3291-1111
Rua Buenos Aires, 15
7º andar
Ed. Buenos
Aires Corporate
Rio de Janeiro, RJ
Brasil
20091-005
T 55 21 3535-2100
T 55 21 3535-2100
Setor Comercial Norte
Quadra 2 Bloco A
Ed. Corporate
Financial Center
6º andar Conjunto 604
Brasília DF Brasil
70712-900
T 55 61 3426-8000
F 55 61 3426-8099
Av. Carlos Gomes 222
Ed. Opus One 5º andar
Porto Alegre RS Brasil
90480-000
T 55 51 3025-2200
F 55 51 3025-2222
Av. Dr. José Bonifácio
Coutinho Nogueira 150
8º andar
Campinas SP Brasil
13091-611
T 55 19 3207-3666
F 55 19 3202-2375
Rua Dr. Montaury 2090
5º andar
Caxias do Sul RS Brasil
95020-190
T 55 54 3534-8464
150 East 58th Street
16th andar
New York NY USA
10155
T 1 212 698-1445
F 1 212 698-1144
© TozziniFreire Advogados. Todos os direitos reservados.
Deixe uma resposta